The second major trial evaluated a maximum of 6 courses of either paclitaxel (135 mg/ m² over 24 hours) followed by cisplatin (75 mg/ m²) or control in over 400 patients with stage III/ IV primary ovarian cancer, with a > 1 cm residual disease after staging laparotomy, or with distant metastases.